Medicamen Organics Past Earnings Performance

Past criteria checks 4/6

Medicamen Organics has been growing earnings at an average annual rate of 49.3%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 29.9% per year. Medicamen Organics's return on equity is 9.3%, and it has net margins of 8.3%.

Key information

49.3%

Earnings growth rate

45.2%

EPS growth rate

Pharmaceuticals Industry Growth	17.5%
Revenue growth rate	29.9%
Return on equity	9.3%
Net Margin	8.3%
Last Earnings Update	30 Sep 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Medicamen Organics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NSEI:MEDIORG Revenue, expenses and earnings (INR Millions)
Date	Revenue	Earnings	G+A Expenses
30 Sep 24	308	26	35
30 Jun 24	280	25	35
31 Mar 24	253	24	34
31 Mar 23	221	10	33
31 Mar 22	210	1	29
31 Mar 21	250	2	28
31 Mar 20	315	1	30

Quality Earnings: MEDIORG has a high level of non-cash earnings.

Growing Profit Margin: MEDIORG's current net profit margins (8.3%) are higher than last year (7.1%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: MEDIORG's earnings have grown significantly by 49.3% per year over the past 5 years.

Accelerating Growth: MEDIORG's earnings growth over the past year (51.3%) exceeds its 5-year average (49.3% per year).

Earnings vs Industry: MEDIORG earnings growth over the past year (51.3%) exceeded the Pharmaceuticals industry 20.4%.

Return on Equity

High ROE: MEDIORG's Return on Equity (9.3%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/23 07:41
End of Day Share Price	2024/12/19 00:00
Earnings	2024/09/30
Annual Earnings	2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Medicamen Organics Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution